Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | — |
The patient missed a dose of Vivotif; Case reference number US-BN-2025-00111 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV25-1493) on 23-Jun-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took dose of Vivotif (batch number: unknown), at an unknown dose, route for unknown indication. As reported, the patient that missed a dose of Vivotif and would take the dose later that expected (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age missed a dose of Vivotif for unknown indication, which is considered as missed dose. It was unknown if the patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age missed a dose of Vivotif for unknown indication, which is considered as missed dose. It was unknown if the patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.